Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.01 USD | +0.25% | -4.74% | +14.20% |
Mar. 14 | Top Premarket Gainers | MT |
Mar. 13 | Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 17.12M |
---|---|---|---|---|---|
Net income 2024 * | -21M | Net income 2025 * | -24M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.01
x | P/E ratio 2025 * |
-1.41
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.13% |
1 day | -1.05% | ||
1 week | -8.03% | ||
Current month | -7.60% | ||
1 month | -14.32% | ||
3 months | +17.94% | ||
6 months | -19.48% | ||
Current year | +13.92% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Newman
FOU | Founder | 68 | 21-02-23 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 21-08-02 |
Nir Sassi
DFI | Director of Finance/CFO | 48 | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Hayes
BRD | Director/Board Member | 58 | 21-08-02 |
Jeffrey Meckler
CEO | Chief Executive Officer | 57 | 21-08-02 |
Robert Martell
BRD | Director/Board Member | 61 | 23-01-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 2.01 | +0.25% | 718 |
24-05-02 | 2.005 | -1.05% | 11,717 |
24-05-01 | 2.026 | -6.63% | 21,270 |
24-04-30 | 2.17 | +2.27% | 4,847 |
24-04-29 | 2.122 | +0.56% | 7,724 |
Delayed Quote Nasdaq, May 02, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.92% | 17.12M | |
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+46.56% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |
- Stock Market
- Equities
- INDP Stock